`

Immix Biopharma (Nasdaq: IMMX)

Biotechnology

Sign Up to View More
revenue-icon Revenue
11M - 100M
funding-icon Total Funding
$15.0M
size-icon Size
11 - 50
About Us
Org Charts
Employees
Buyer Intent
Tech Stack
Jobs

Frequently Asked Questions About Immix Biopharma (Nasdaq: IMMX)

What does Immix biopharma (nasdaq: immx) do?+

Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other autoimmune diseases. Our lead cell therapy is FDA IND cleared next generation CAR-T NXC-201, currently being evaluated in our ongoing Phase 1b/2 NEXICART-1 (NCT04720313) clinical trial, initiated in February 2021. NXC-201 has the potential to be the worlds first Single-Day CRS CAR-T (CRS median onset day 1, median duration 1 day), enabling the potential for a faster return home for patients and supporting ongoing expansion into autoimmune indications. NXC-201 has been awarded Orphan Drug Designation (ODD) by the FDA in both...

What is Immix biopharma (nasdaq: immx)'s industry? +

Immix biopharma (nasdaq: immx) operates in the Biotechnology industry.

What is Immix biopharma (nasdaq: immx)'s revenue? +

Immix biopharma (nasdaq: immx)'s revenue is 11m - 100m

What is Immix biopharma (nasdaq: immx)'s company size? +

Immix biopharma (nasdaq: immx) has 11 - 50 employees.

The Go-to Sales Technology According to G2

G2 Badges Map
Get Started With Clodura
Sign Up

Sign Up for Free

Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.

Sign Up For Free
Supercharge Your Prospecting

Supercharge Your Prospecting

Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.

Sign Up For Free
Grow Your Business

Grow Your Business

Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.

Sign Up For Free